MRSA Research Today is a free monthly online journal that collates and summarizes the latest research about MRSA, including details on methicillin-resistant staphylococcus aureus, hospitals, infection, antibiotic resistance, superbugs.

Case studies in current drug development: 'glycylcyclines'.

Sum PE

Chemical and Screening Sciences Department, Wyeth Research, 401 North Middletown Road, Pearl River, NY 10965, USA. sump@wyeth.com

Glycylcyclines represent a new class of tetracycline antibiotics with potent antibacterial activities against resistant pathogens. One of the glycylcyclines, Tygacil, was selected for further development and has been approved by the FDA. It has an expanded broad-spectrum of antibacterial activity both in vitro and in vivo. It is active against a wide range of clinically relevant pathogens including Gram-positive, Gram-negative, atypical, and anaerobic bacteria and bacterial strains carrying either or both of the two major forms of tetracycline resistance (efflux and ribosomal protection). Most importantly, it is active against the multiply antibiotic resistant Gram-positive pathogenic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Published 25 July 2006 in Curr Opin Chem Biol, 10(4): 374-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 MRSA Research Today. All Rights Reserved.